TY - JOUR
T1 - Functional disability and its predictors in systemic sclerosis: A study from the DeSScipher project within the EUSTAR group
AU - Jaeger, Veronika K.
AU - Distler, Oliver
AU - Maurer, Britta
AU - Czirják, Laszlo
AU - Lóránd, Veronika
AU - Valentini, Gabriele
AU - Vettori, Serena
AU - Del Galdo, Francesco
AU - Abignano, Giuseppina
AU - Denton, Christopher
AU - Nihtyanova, Svetlana
AU - Allanore, Yannick
AU - Avouac, Jerome
AU - Riemekasten, Gabriele
AU - Siegert, Elise
AU - Huscher, Dörte
AU - Matucci-Cerinic, Marco
AU - Guiducci, Serena
AU - Frerix, Marc
AU - Tarner, Ingo H.
AU - Toth, Beata Garay
AU - Fankhauser, Beat
AU - Umbricht, Jörg
AU - Zakharova, Anastasia
AU - Mihai, Carina
AU - Cozzi, Franco
AU - Yavuz, Sule
AU - Hunzelmann, Nicolas
AU - Rednic, Simona
AU - Vacca, Alessandra
AU - Schmeiser, Tim
AU - Riccieri, Valeria
AU - De la Peña Lefebvre, Paloma García
AU - Gabrielli, Armando
AU - Krummel-Lorenz, Brigitte
AU - Martinovic, Duska
AU - Ancuta, Codrina
AU - Smith, Vanessa
AU - Müller-Ladner, Ulf
AU - Walker, Ulrich A.
N1 - Funding Information:
Funding: This study, as part of the DeSScipher project, was supported by the European Community’s Framework Programme 7 [FP7-HEALTH-2012.2.4.4-2 Observational trials in rare diseases; grant agreement No. 305495].
Funding Information:
Disclosure statement: D.H. received consultancies from Actelion, Switzerland. U.M.-L. is supported by the FP7 program of the European Commission. N.H. has received lecture fees and research support from Actelion and Bayer. Y.A. has received honoraria and/or research support/grants from Actelion, Bayer, Biogen, BMS, Genentech-Roche, Galapagos, Inventiva, Medac, Pfizer, Sanofi, Servier, Union Chimique Belge. O.D. had a consultancy relationship and/or has received research funding from 4 D Science, AbbVie, Actelion, Active Biotec, Bayer, BiogenIdec, Bristol-Myers Squibb, Boehringer Ingelheim, ChemomAb, EpiPharm, espeRare foundation, Genentech/Roche, GlaxoSmithKline, Inventiva, iQone Healthcare, Lilly, medac, Mepha, MedImmune, Pharmacyclics, Pfizer, Sanofi, Serodapharm and Sinoxa in the area of potential treatments of scleroderma and its complications. In addition, O.D. has a patent mir-29 for the treatment of systemic sclerosis licensed. V.L. received personal fees from the European Union Seventh Framework Program (FP7/2007-2013) during the conduct of the study. C.M. has received research support and/or honoraria and has/had consultancy relationship from Abbvie, Actelion, Genetech/Roche and Geneva Romfarm in the area of systemic sclerosis and its complications. B.M. had grant/research support from AbbVie, Protagen, EMDO and Novartis, congress support from Pfizer, Roche, Actelion and has a patent licensed for mir-29 for the treatment of systemic sclerosis. C.D. has received consultancy fees or honoraria from Actelion, Bayer, GSK, CSL Behring, Merck-Serono, Genentech-Roche, Inventiva, Sanofi-Aventis and Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Objectives. The multisystem manifestations of SSc can greatly impact patients' quality of life. The aim of this study was to identify factors associated with disability in SSc. Methods. SSc patients from the prospective DeSScipher cohort who had completed the scleroderma health assessment questionnaire (SHAQ), a disability score that combines the health assessment questionnaire and five visual analogue scales, were included in this analysis. The effect of factors possibly associated with disability was analysed with multiple linear regressions. Results. The mean SHAQ and HAQ scores of the 944 patients included were 0.87 (S.D. = 0.66) and 0.92 (S.D. = 0.78); 59% of the patients were in the mild to moderate difficulty SHAQ category (0≤SHAQ<1), 34% in the moderate to severe disability category (1≤SHAQ<2) and 7% in the severe to very severe disability category (2≤SHAQ≤3). The means of the visual analogue scales scores were in order of magnitude: overall disease severity (37 mm), RP (31 mm), pulmonary symptoms (24 mm), gastrointestinal symptoms (20mm) and digital ulcers (19 mm). In multiple regression, the main factors associated with high SHAQ scores were the presence of dyspnoea [modified New York Heart Association (NYHA) class IV (regression coefficient B= 0.62), modified NYHA class III (B = 0.53) and modified NYHA class II (B = 0.21; all vs modified NYHA class I)], FM (B = 0.37), muscle weakness (B = 0.27), digital ulcers (B = 0.20) and gastrointestinal symptoms (oesophageal symptoms, B= 0.16; stomach symptoms, B= 0.15; intestinal symptoms, B= 0.15). Conclusion. SSc patients perceive dyspnoea, pain, digital ulcers, muscle weakness and gastrointestinal symptoms as the main factors driving their level of disability, unlike physicians who emphasize objective measures of disability.
AB - Objectives. The multisystem manifestations of SSc can greatly impact patients' quality of life. The aim of this study was to identify factors associated with disability in SSc. Methods. SSc patients from the prospective DeSScipher cohort who had completed the scleroderma health assessment questionnaire (SHAQ), a disability score that combines the health assessment questionnaire and five visual analogue scales, were included in this analysis. The effect of factors possibly associated with disability was analysed with multiple linear regressions. Results. The mean SHAQ and HAQ scores of the 944 patients included were 0.87 (S.D. = 0.66) and 0.92 (S.D. = 0.78); 59% of the patients were in the mild to moderate difficulty SHAQ category (0≤SHAQ<1), 34% in the moderate to severe disability category (1≤SHAQ<2) and 7% in the severe to very severe disability category (2≤SHAQ≤3). The means of the visual analogue scales scores were in order of magnitude: overall disease severity (37 mm), RP (31 mm), pulmonary symptoms (24 mm), gastrointestinal symptoms (20mm) and digital ulcers (19 mm). In multiple regression, the main factors associated with high SHAQ scores were the presence of dyspnoea [modified New York Heart Association (NYHA) class IV (regression coefficient B= 0.62), modified NYHA class III (B = 0.53) and modified NYHA class II (B = 0.21; all vs modified NYHA class I)], FM (B = 0.37), muscle weakness (B = 0.27), digital ulcers (B = 0.20) and gastrointestinal symptoms (oesophageal symptoms, B= 0.16; stomach symptoms, B= 0.15; intestinal symptoms, B= 0.15). Conclusion. SSc patients perceive dyspnoea, pain, digital ulcers, muscle weakness and gastrointestinal symptoms as the main factors driving their level of disability, unlike physicians who emphasize objective measures of disability.
UR - http://www.scopus.com/inward/record.url?scp=85043311396&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kex182
DO - 10.1093/rheumatology/kex182
M3 - Journal articles
C2 - 28499034
AN - SCOPUS:85043311396
SN - 1462-0324
VL - 57
SP - 441
EP - 450
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 3
ER -